NCT00181688View on ClinicalTrials.gov

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Ovarian CancerPeritoneal CarcinomaTubal Carcinoma
Interventions
DRUG

Iressa (ZD1839)

DRUG

Arimidex (Anastrozole)

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00181688 - Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter